Get the Stockscreener App
18.93
1.66%
0.31
After Hours:
18.93
Upstream Bio Inc stock is traded at $18.93, with a volume of 424.80K.
It is up +1.66% in the last 24 hours and up +69.93% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$18.62
Open:
$18.68
24h Volume:
424.80K
Relative Volume:
0.93
Market Cap:
$1.02B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-14.73
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+18.31%
1M Performance:
+69.93%
6M Performance:
+149.08%
1Y Performance:
+0.00%
1-Day Range:
$18.15
$19.27
1-Week Range:
$15.64
$19.27
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
18.93 | 1.00B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Building trade automation scripts for Upstream Bio Inc.July 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - Newser
Has Upstream Bio Inc. formed a bullish divergencePortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
XTX Topco Ltd Takes $78,000 Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
What to expect from Upstream Bio Inc. in the next 30 daysEarnings Summary Report & Community Trade Idea Sharing - Newser
Real time breakdown of Upstream Bio Inc. stock performancePortfolio Risk Summary & Real-Time Market Sentiment Reports - Newser
Upstream Bio Inc. stock momentum explainedEarnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
Analyzing recovery setups for Upstream Bio Inc. investorsWeekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Analyzing net buyer seller activity in Upstream Bio Inc.Fed Meeting & Intraday High Probability Alerts - Newser
Real time social sentiment graph for Upstream Bio Inc.2025 Growth vs Value & Fast Exit Strategy with Risk Control - Newser
Tools to assess Upstream Bio Inc.’s risk profileDollar Strength & Real-Time Volume Surge Alerts - Newser
Is it too late to sell Upstream Bio Inc.Trade Exit Summary & Safe Entry Zone Identification - Newser
Upstream Bio (UPB) Q2 R&D Soars 169% - AOL.com
Can Upstream Bio's (UPB) Rising Losses Outpace Revenue Growth in Its Long-Term Strategy? - simplywall.st
Upstream Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern Forming - Newser
Ichimoku Cloud Indicates Uncertainty Around Upstream Bio Inc.July 2025 Volume & Reliable Entry Point Alerts - sundaytimes.kr
Short interest data insights for Upstream Bio Inc.Quarterly Trade Review & AI Based Buy and Sell Signals - Newser
Upstream Bio Appoints Stacy Price as Chief Technology Officer - The Globe and Mail
Upstream Bio Inc. stock retracement – recovery analysisFree Reliable Chart-Based Trade Entries - Newser
Comparing Upstream Bio Inc. in custom built stock radarsFree Short Term Buy Zone Stock Alerts - Newser
What makes Upstream Bio Inc. stock price move sharplyForecasting Stock Moves with AI Insights - Newser
How Efficient Is Upstream Bio Inc. at Controlling Operating CostsChart Signal and Short-Term Forecast Tracker - Newser
Tools to monitor Upstream Bio Inc. recovery probabilityHigh Reward Picks with Tight Risk Control - Newser
Q3 EPS Estimates for Upstream Bio Decreased by William Blair - Defense World
Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
How to manage a losing position in Upstream Bio Inc.Free Expert Verified Stock Trade Ideas - Newser
How to use a screener to detect Upstream Bio Inc. breakoutsFree Day Trading Signals With High Precision - Newser
Upstream Bio 2025 Q2 Earnings Net Loss Widens Despite Revenue Surge - AInvest
Upstream Bio, Inc. Reports Increased R&D Investments - TipRanks
Key resistance and support levels for Upstream Bio Inc.Free Swing Trade With Risk Management - Newser
Positive Outlook for Upstream Bio, Inc. Driven by Promising Clinical Trial Developments - TipRanks
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):